Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT versus REVERSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT versus REVERSOL.
ARICEPT vs REVERSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft of the central nervous system.
Reversal agent for neuromuscular blockade; inhibits acetylcholinesterase, increasing acetylcholine concentration at nicotinic receptors to reverse nondepolarizing neuromuscular blocking agents.
Initial: 5 mg orally once daily for 4-6 weeks; may increase to 10 mg once daily. Maximum: 10 mg per day. Route: oral. Frequency: once daily.
0.25-0.5 mg/kg IV bolus over 10 seconds, repeated if necessary up to a maximum total dose of 2 mg/kg.
None Documented
None Documented
70 hours (terminal elimination half-life; steady-state reached in 15-21 days; once-daily dosing appropriate)
Terminal elimination half-life is 8-12 hours in healthy adults (mean 10 hours). In hepatic impairment, increases up to 18 hours; in severe renal impairment (CrCl <30 mL/min), half-life may extend to 24 hours.
Renal (57% unchanged drug, 17% as metabolites), fecal (30%), biliary (minimal)
Primarily renal excretion of unchanged drug (60-70%). Fecal elimination accounts for 20-25% via biliary secretion. Minor metabolism (<10%) with metabolites also renally cleared.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor